Portal Hypertensive Gastropathy in Liver Cirrhosis: Prevalence, Natural History, and Risk Factors

Ken Nishino¹, Miwa Kawanaka¹, Noriaki Manabe², Mitsuhiko Suehiro¹, Hirofumi Kawamoto¹ and Ken Haruma¹

Abstract:
Objective Portal hypertensive gastropathy (PHG) is a common finding in patients with liver cirrhosis (LC) and may cause both acute and chronic bleeding. A number of risk factors for PHG have been identified. The present study explored the characteristics of Japanese patients with LC who develop PHG.

Methods Clinical findings (age, sex, etiology, the presence of esophageal varices, splenomegaly and severity of LC), laboratory data, and whether or not atrophic gastritis was found on endoscopy were retrospectively reviewed in patients with LC who had undergone esophagogastroduodenoscopy. PHG was endoscopically graded as absent, mild, or severe.

Results Of 262 patients with LC (mean age, 69 years old; 145 men), 158 had no PHG, 41 had mild PHG, and 63 had severe PHG. In a univariate analysis, a younger age, male sex, non-viral etiology, absence of atrophic gastritis, presence of esophageal varices, splenomegaly, severe LC, low platelet count, and low hemoglobin concentration were associated with PHG. A multivariate analysis showed a significant association of PHG with the absence of atrophic gastritis (p<0.048), presence of esophageal varices (p<0.001), non-viral etiology (p<0.033), splenomegaly (p<0.048), and severe LC (p<0.005). There were no cases of massive bleeding from PHG during follow-up.

Conclusion Esophageal varices, splenomegaly, severe liver cirrhosis, the absence of atrophic gastritis, and etiology were found to be risk factors for PHG in Japanese patients.

Key words: portal hypertensive gastropathy, liver cirrhosis, atrophic gastritis, esophageal varices, splenomegaly

(Intern Med 61: 605-613, 2022) (DOI: 10.2169/internalmedicine.7943-21)

Introduction

Portal hypertensive gastropathy (PHG) is a common endoscopic finding in patients with liver cirrhosis (LC) (1-3). It is a known cause of anemia and acute or insidious gastrointestinal (GI) bleeding as well as esophageal and gastric varices and gastric antral vascular ectasia in these patients (4-6). The reported prevalence of PHG varies from 3.7% to 75% in patients with portal hypertension (3) and from 15.1% to 100% in patients with LC (3). This wide variability likely reflects variability in definitions, classification criteria, interpretation of endoscopic findings, patient selection, and severity of liver impairment.

McCormack et al. classified PHG with features of fine pink speckling (scarlatina-type rash) and a mosaic pattern (snakeskin appearance) as mild and that with discrete red spots or diffuse hemorrhagic lesions as severe (7) (Fig. 1). This endoscopic classification is important because of the increased risk of gastric hemorrhaging in severe cases of PHG (4, 8, 9).

Histologic evidence of gastritis and various endoscopic findings, including redness, swelling, erosions, atrophy, enlarged folds, and nodularity, have been found in patients with Helicobacter pylori (H. pylori) infection (10). In some cases, the findings of redness and swelling caused by H. py-
Figure 1. Typical endoscopic findings for portal hypertensive gastropathy. A mosaic pattern (snakeskin appearance) (mild, a) and discrete red spots (severe, b) can be seen.

\textit{H. pylori} are similar to the endoscopic findings for PHG. Furthermore, anti-reflux agents, such as proton pump inhibitors (PPIs), cause specific changes in the gastric mucosa, including a cobble-stone appearance (11), gastric polyps (11), and black spots (12). PPIs are widely used in patients with LC, especially those with esophageal or gastric varices, and may influence the endoscopic findings in the gastric mucosa. Therefore, there may be cases in which it is difficult to distinguish between PHG and \textit{H. pylori}-positive gastritis or PPI-induced gastropathy.

Although there have been many clinicopathologic studies of PHG (13-15), there are no recent reports on the frequency of PHG, the factors involved in its occurrence, or its prognosis in Japan (16). Considerable progress has been made in the treatment of LC, including the use of PPIs and targeted treatment of \textit{H. pylori}, which is involved in inflammation of the gastric mucosa. However, there is a possibility of changes in the endoscopic findings, pathophysiology, and clinical course in patients with PHG. Therefore, to ensure good clinical practice, we investigated the clinical characteristics of PHG detected by experienced endoscopists at our institution.

The present study assessed the prevalence of PHG in patients with LC at Kawasaki Medical School and clarified the factors associated with the development of PHG in Japan.

Materials and Methods

This retrospective cross-sectional study included adult patients (\geq 20 years old) with an established diagnosis of LC who underwent esophagogastrroduodenoscopy at Kawasaki Medical University between April 2014 and March 2020. Patients were consecutively enrolled. Laboratory data, clinical images, including endoscopic findings, and details of their social history (use of gastric acid secretion inhibitors and other drugs) were collected from medical records as available.

The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments and was approved by the ethics committee of Kawasaki Medical University. All patients consented to undergo the endoscopic procedure. The need for specific informed consent for inclusion in this report was waived in view of the retrospective study design, the anonymity of the data, and the routine nature of all clinical procedures and tests performed.

Selection criteria

The diagnosis of LC was made primarily based on imaging findings. The findings were comprehensively judged based on the bluntness/rounding or irregularity of the liver edge, regenerative nodules in the liver parenchyma, evidence of portal hypertension, such as splenomegaly and a collateral circulation, and changes in the shape of the liver, such as right lobe atrophy (17). Histology reports were also examined as necessary. Patients who had undergone liver transplantation or gastrectomy, those with advanced cancer and tumor thrombus in the portal vein, those with non-cirrhotic portal hypertension, those in whom endoscopic observation was inadequate, and those who have been taking antibiotics or other drugs for that affect \textit{H. pylori} infection or gastric mucosal atrophy were excluded.

Endoscopy

The GI tract was evaluated for PHG, gastric mucosal atrophy, and esophageal varices by three doctors (2 board-certified fellows of the Japan Gastroenterological Endoscopy Society with more than 20 years of endoscopic experience who were familiar with the diagnosis of \textit{H. pylori} infection gastritis, and a board-certified hepatologist of the Japan Society of Hepatology with more than 15 years of endoscopic experience). Each case was compared with clear endoscopic images presented in the literature and performed under consensus (18, 19). With the recent advancement of endoscopic image analysis technology, the diagnosis rate of PHG is expected to improve using image enhancement systems, such as narrow-band imaging (NBI) and blue-laser imaging.
Figure 2. Narrow-band imaging (NBI) image of portal hypertensive gastropathy. (a) White-light imaging image, b) NBI image; the NBI image shows vasodilatation and the boundaries of the gastric area more clearly.

Assessments of splenomegaly

Splenomegaly was assessed by ultrasound imaging. According to the definition of the Japanese Society of Sonographers, splenomegaly was defined in cases with a Spleen Index (product of the diameter from the hilum to the anterior margin of the spleen and the diameter perpendicular) >20 cm².

Stratifying severity of liver disease

Data were collected for the complete blood count, renal and liver function tests, abdominal ultrasonography, abdominal computed tomography, prothrombin time, and international normalized ratio. The severity of liver disease was assessed by the Child-Pugh class (23, 24) and the model for end-stage liver disease (MELD) score (25). The patients were stratified into two groups according to the Child-Pugh class: A (5-6) and B/C (7-15).

Statistical analyses

Continuous variables are reported as the mean and standard error of the mean or as the median [interquartile range (IQR)]. Categorical variables are summarized as the number and percentage. Continuous variables were compared using logistic regression analyses or the chi-squared test as applicable. Univariate and multivariate logistic regression analyses were performed to assess the risk factors for PHG. All statistical analyses were performed using the JMP 14 software program (SAS Institute, Cary, USA). A 2-sided p value of ≤0.05 was considered statistically significant.

Results

The clinical characteristics and results of univariate analyses are summarized in Tables 1 and 2. Thirty-one of the 293 patients screened were excluded, leaving data for 262 patients with cirrhosis available for inclusion in the study (Fig. 3).

Patient demographics

One hundred and four (39.7%) of the 262 patients with LC had PHG (mild, n=41; severe, n=63), and 158 (60.3%) had no PHG.

Etiology

The cause of cirrhosis was chronic viral hepatitis B or C in 145 patients (55.3%), alcohol in 50 (19.1%), and other (e.g., nonalcoholic steatohepatitis, primary biliary cholangitis) in 67 (25.6%). The prevalence of PHG in patients with alcohol-induced LC was significantly higher than that of viral LC [62% (31/50) vs. 32.4% (47/145), p<0.001] and other etiologies [62% (31/50) vs. 38.8% (26/67), p<0.014], but there was no significant difference between the rates of viral LC and other etiologies [32.4% (47/145) vs. 38.8% (26/67), p<0.363].

Endoscopy

According to the Kimura-Takemoto classification, 165 cases had closed-type gastric mucosal atrophy, and 97 cases
Table 1. Clinical Characteristics of Patients in This Study.

| Patients (n) | 262 |
|--------------|-----|
| Age (years)  | 69.0±11.2 |
| Sex (n, %)    | Male 145 (55.3) |
|              | Female 117 (44.7) |
| Etiology (n, %) | Viral 145 (55.3) |
|              | Non-viral 117 (44.7) |
| PHG (n, %)     | 104 (39.7) |
| Atrophy (Kimura-Takemoto classification) (n, %) | Closed type 165 (63.0) |
|              | Open type 97 (37.0) |
|              | C1/C2/C3 128/28/9 |
|              | O1/O2/O3 48/24/25 |
| Esophageal varices (n, %) | 133 (50.8) |
| Distribution  | esophageal only 100 (38.2) |
|              | esophagogastric 33 (12.6) |
|              | gastric only 6 (2.3) |
| Esophageal varices | Li/Lm/Ls 23/76/34 |
|                | F1/F2/F3 80/46/7 |
|                | RC0/RC1/RC2/RC3 96/22/10/5 |
| Treatment      | ALL 43 |
|                | EVL 21 |
|                | EIS 17 |
|                | BRTO 5 |
| Time from treatment (years) | 3.19±3.85 |
| GAVE (n, %)    | 30 (11.5) |
| Splenomegaly (n, %) | 139 (54.1) |
| Child-Pugh class | A 180 (68.7) |
|                | B 62 (23.7) |
|                | C 20 (7.6) |
| MELD score     | 8 [7-11] |
| PLT            | 110 [78-149] |
| Hb             | 12.5 [10.6-14.1] |
| AST            | 37 [26-57] |
| ALT            | 24 [18-43] |
| GGT            | 45 [26-90] |
| Bil            | 1.0 [0.7-1.4] |
| Alb            | 3.8 [3.3-4.2] |
| ChE            | 208 [140-275] |
| T-Chol         | 163 [133-194] |
| Cre            | 0.77 [0.63-0.96] |
| NH3            | 41 [29-65] |
| Gastric acid secretion inhibitor (n, %) | 145 (55.3) |

Continuous variables are reported as mean±standard error, or median [interquartile range].

Li: location inferior, Lm: location medium, Ls: location superior, F: form, RC: red color sign, EVL: Endoscopic variceal ligation, EIS: Endoscopic injection sclerotherapy, BRTO: balloon-occluded transjugular obliteration, MELD: Model for End-Stage Liver Disease, PLT: Platelets 10^9/L, Hb: Hemoglobin g/dL, AST: Aspartate aminotransferase IU/L, ALT: Alanine aminotransferase IU/L, GGT: Gamma-glutamyl transferase IU/L, Bil: Bilirubin mg/dL, Alb: Albumin g/dL, ChE: Cholinesterase IU/L, T-Chol: Total cholesterol mg/dL, Cre: Creatinine mg/dL.

had the open type. The prevalence of the closed type was significantly higher in patients with PHG than in those without PHG [73.1% (76/104) vs. 56.3% (89/158), p<0.006]. The rate of *H. pylori* infection was 43.5% in the PHG group and 55.1% in the non-PHG group (p<0.018). One hundred and thirty-three patients (50.8%) had esophageal varices; the prevalence of esophageal varices was significantly higher in patients with PHG than in those without PHG [75.0% (78/104) vs. 34.8% (55/158), p<0.001]. Furthermore, the prevalence of PHG was slightly higher in patients with concomitant gastric and esophageal varices than in those with esophageal varices only [69.7% (23/33) vs. 55% (55/100)].
Table 2. Comparison of Clinicopathological Characteristics between Patients with and without Portal Hypertensive Gastropathy.

|                  | PHG n=104 | No PHG n=158 | p value |
|------------------|-----------|--------------|---------|
| **Age (years)**  | 67±11.8   | 70±10.6      | 0.03    |
| **Sex (n, %)**   | Male 67 (64.4) | 78 (49.4) | 0.016   |
|                  | Female 37 (35.6) | 80 (50.6) |           |
| **Etiology (n, %)** |       |              |         |
| Viral            | 47 (45.2)  | 98 (62.0)    | 0.007   |
| Non-viral        | 57 (54.8)  | 60 (38.0)    |           |
| **Atrophy**      |            |              |         |
| (Kimura-Takemoto classification) | | |         |
| Closed type      | 76 (73.1)  | 89 (56.3)    | 0.006   |
| Open type        | 28 (26.9)  | 69 (43.7)    |           |
| **Distribution** |            |              |         |
| esophageal only  | 55 (52.9)  | 45 (28.5)    | <0.001  |
| esophagogastric  | 23 (22.1)  | 10 (6.3)     | <0.001  |
| gastric only     | 1 (1.0)    | 5 (3.2)      | 0.216   |
| **Esophageal varices** |      |              |         |
| Li/Lm/Ls         | 12/44/22   | 11/32/12     | 0.627   |
| F1/F2/F3         | 41/35/2    | 39/11/5      | 0.005   |
| RC0/RC1/RC2/RC3  | 51/17/2    | 71/11/7      | 0.013   |
| **Treatment (n, %)** |       |              |         |
| ALL              | 34 (32.7)  | 9 (5.7)      | <0.001  |
| EVL              | 15 (14.4)  | 6 (3.8)      | 0.433   |
| EIS              | 15 (14.4)  | 2 (1.3)      |         |
| BRTO             | 4 (3.8)    | 1 (0.6)      |         |
| **Time from treatment (years)** | 2.69±2.86 | 5.08±6.25 | 0.119 |
| **GAVE (n, %)**  | 13 (12.5)  | 17 (10.8)    | 0.666   |
| **Splenomegaly (n, %)** | 73 (70.2) | 66 (41.8) | <0.001 |
| A                | 52 (50.0)  | 128 (81.0)   | <0.001  |
| B                | 35 (33.7)  | 27 (17.1)    |         |
| C                | 17 (16.3)  | 3 (1.9)      |         |
| **MELD score**   | 9 [8-14]   | 8 [6-10]     | <0.001  |
| **PLT**          | 93 [62-139] | 117 [86-156] | 0.001   |
| **Hb**           | 11.5 [9.7-13.2] | 13.3 [11.3-14.7] | <0.001 |
| **AST**          | 40 [27-62] | 36 [26-53]   | 0.116   |
| **ALT**          | 23 [18-43] | 25 [17-40]   | 0.806   |
| **GGT**          | 56 [31-96] | 40 [24-77]   | 0.043   |
| **Bil**          | 1.2 [0.8-1.7] | 0.9 [0.7-1.3] | 0.005  |
| **Alb**          | 3.5 [2.9-3.9] | 4.0 [3.5-4.3] | <0.001 |
| **ChE**          | 160 [103-225] | 237 [176-298] | <0.001 |
| **T-Cho**        | 150 [125-179] | 172 [138-201] | 0.001  |
| **Cre**          | 0.82 [0.64-1.0] | 0.75 [0.62-0.95] | 0.267  |
| **NH₃**          | 49.5 [34.8-78.3] | 35.5 [25.3-48.8] | <0.001 |
| **Gastric acid secretion inhibitor (n, %)** | 68 (65.4) | 77 (48.7) | 0.008 |

Continuous variables are reported as mean±standard error, or median [interquartile range].

Li: location inferior, Lm: location medium, Ls: location superior, L: location, F: form, RC: red color sign, EVL: Endoscopic variceal ligation, EIS: Endoscopic injection sclerotherapy, BRTO: balloon-occluded transcervical obliteration, MELD: Model for End-Stage Liver Disease, PLT: Platelets 10⁹/L, Hb: Hemoglobin g/dL, AST: Aspartate aminotransferase IU/L, ALT: Alanine aminotransferase IU/L, GGT: Gamma-glutamyl transferase IU/L, Bil: Bilirubin mg/dL, Alb: Albumin g/dL, ChE: Cholinesterase IU/L, T-Cho: Total cholesterol mg/dL, Cre: Creatinine mg/dL.

Severity of liver disease

In terms of the severity of liver disease, 180 patients (68.7%) were in Child-Pugh class A, 62 were in Child-Pugh class B, and 20 were in Child-Pugh class C. The prevalence of PHG significantly increased as the Child-Pugh class became more severe [A vs. B: 28.9% (52/180) vs. 56.5% (35/62), p<0.001, A vs. C: 28.9% (52/180) vs. 85.0% (17/20), p<0.001, B vs. C: 56.5% (35/62) vs. 85.0% (17/20), p<0.029].

Multivariate analyses

In the multivariate analyses, gastric mucosal atrophy, etiology of LC, presence of esophageal varices, splenomegaly,
and severe liver disease remained significant risk factors for PHG (Table 3).

**Factors that predict the development of PHG**

The factors predicting the development of PHG were examined in terms of splenomegaly (Spleen Index) and the Child-Pugh score. As a result, the cut-off value was 19.5 for the Spleen Index and 6 for the Child-Pugh score (Fig. 4).

**Natural history**

Fifty-three patients in the PHG group were followed up by an endoscopic examination for at least one year. During a mean follow-up period of 3.94±2.2 (range 1-6) years, the PHG worsened in 4 patients, improved in 5, disappeared in 11, and remained unchanged in 33.
A case of portal hypertensive gastropathy. (a) Endoscopic image of the gastric body observed from the gastric angle. (b) Look-down image of the gastric body. The boundary between the atrophic mucosa, through which blood vessels are clearly visible, and the non-atrophic mucosa is clear. In PHG cases with atrophic gastritis, the findings of PHG may be masked by a reduced gastric mucosal blood flow.

**Discussion**

In this study, experienced endoscopists found that 39.7% of 262 Japanese patients with LC at our institution had PHG, which was mild in 39.4% of cases and severe in 60.6%. Risk factors for the development of PHG were the absence of atrophic gastritis, presence of esophageal varices, splenomegaly, and severe liver impairment.

This is the first report on the association between atrophic gastritis and PHG. Our multivariate analysis revealed that the prevalence of PHG was significantly higher in patients without atrophic gastritis (p<0.048). Earlier studies indicated that *H. pylori* infection is not associated with the development of PHG (26, 27) and that the prevalence of *H. pylori* is lower in patients with PHG (28). The evaluation of *H. pylori* infection based on the Kyoto classification of gastritis (29) showed that *H. pylori* infection was not involved in the development of PHG in this study. Although there are still conflicting data regarding whether the gastric mucosal blood flow is increased or decreased in patients with PHG (30), a significant increase in gastric mucosal blood flow was suggested in rodent models of PHG (31, 32) and portal hypertension (33). In a study in humans by Takaya et al., the results obtained using the gastric mucosal hemoglobin index suggested that the gastric mucosal blood flow decreased with increasing severity of atrophy (34). Therefore, in PHG cases with atrophic gastritis, the findings of PHG may be masked by reduced gastric mucosal blood flow (Fig. 5).

The multivariate analysis in this study also showed a significant association between PHG and the presence of esophageal varices and splenomegaly (p<0.002). Furthermore, the frequency of PHG was significantly higher in patients with coexisting gastric and esophageal varices. Some studies found no correlation between PHG and the presence of esophageal varices (35, 36), whereas other studies did find a correlation (37-39). In the New Italian Endoscopic Club study, the prevalence of PHG was significantly higher in patients with esophageal varices [77% (80/104)] than in those without esophageal varices [61% (51/84), p<0.007] (5). Fontana et al. also demonstrated a strong positive association between PHG and the presence of esophageal varices (p<0.001) in a large cohort of patients with chronic hepatitis C virus infection and bridging fibrosis/compensated cirrhosis (37). In a prospective study of 331 patients with LC in South Korea, the severity of PHG was correlated with the portal and splenic vein diameters and the size of the spleen (38). In another study by Anegawa et al., laparoscopic splenectomy had a beneficial effect on severe PHG in 16 of 17 patients (16). These results are consistent with our current finding of a correlation between splenomegaly and PHG.

Previous reports on gastric varices have been mixed. Some reports suggest that stasis of blood flow in the gastric mucosa improves when gastric varices appear (40); however, we found no relationship between the prevalence of PHG and gastric varices.

In the present study, severe liver disease, as evaluated by the Child-Pugh class, was an independent risk factor for PHG in a multivariate analysis. The prevalence of PHG increased according to the severity of liver disease [A, 28.9% (52/180); B, 56.5% (35/62); C, 85.0% (17/20)]. Some studies have demonstrated a significant association of PHG with the presence or severity of hepatic impairment (37, 39), although others found no such correlation (41). These conflicting data may reflect the fact that this association is not observed in all stages of liver disease. In the present study, Child-Pugh class B and C were combined and compared with Child-Pugh class A. De Lisi et al. reported that the prevalence of PHG was significantly higher in patients with Child-Pugh class B or C liver disease than in those with class A (42). Furthermore, Sarin et al. reported the prevalence of PHG to be 87% in patients with Child-Pugh class C but only 13% in those with Child-Pugh class A (39).
In this study, the Spleen Index and Child-Pugh score were investigated as predictors of the development of PHG. The Spleen Index was 19.5, which is in agreement with the diagnosis of splenomegaly (20). However, a Child-Pugh score of 6 predicted the development of PHG earlier than a Child-Pugh class B/C (score 7-15), and the specificity of a Child-Pugh score of 7 was 81.0%, which was also considered a useful factor.

In the univariate analysis, the prevalence of PHG was significantly higher in patients with alcohol-induced LC than in those with LC with a viral (p<0.001) or other etiology (p<0.014). The reason for the discrepancy in the findings (13) is unclear but may reflect recent developments in the treatment of viral hepatitis or the direct effect of alcohol, which damages the gastric mucosa and may contribute to the development of PHG (43, 44).

The natural history of PHG needs to be clarified because of its propensity to cause anemia and fatal acute GI bleeding (4-6). Reports on the prevalence of acute upper GI bleeding in patients with PHG have been inconsistent. The frequency of acute GI bleeding in patients with PHG was 2.5% in the study by Primignani et al. (5) and 20% in the study by Stewart et al. (8). Furthermore, in a study by McCormack et al., bleeding occurred in 29 (44.6%) of 65 patients (7). This variability in reporting is partly due to inaccuracies in the endoscopic diagnosis of PHG per se and in the endoscopic diagnosis of PHG as the cause of bleeding. Major risk factors for bleeding in patients with PHG are an increased duration (4, 5) and severity (4, 8, 9) of PHG. Over 90% of cases of acute bleeding occur in patients with severe PHG, with <10% occurring in those with mild PHG (6, 9, 45). Other risk factors for bleeding in patients with PHG include advanced cirrhosis (37, 39) and prior endoscopic eradication of esophageal varices (9). In the present study, we reviewed the endoscopic findings of 53 patients who were able to be followed up for at least 1 year and found no marked change in PHG in 33 cases (62.3%), exacerbation in 4 cases (7.5%), and improvement or disappearance in 16 cases (30.2%). Surprisingly, there were no episodes of acute bleeding from PHG in this study, although there were four cases of acute bleeding among patients with gastric antral vascular ectasia.

This study has several limitations that should be considered when interpreting its results. First, it had a retrospective design. Second, it was a single-center study involving a relatively small number of patients with LC. Third, not all cases were followed up to evaluate the natural history of PHG. The incidence of LC caused by viral infection, which causes PHG, has been declining in Japan, but that of nonalcoholic steatohepatitis is increasing. Therefore, it is important to investigate the clinical characteristics of PHG as revealed in this study in more recent cases.

**Conclusion**

The findings of this study suggest that esophageal varices, splenomegaly, severe liver cirrhosis, absence of atrophic gastritis, and etiology are risk factors for PHG in Japanese patients.

**The authors state that they have no Conflict of Interest (COI).**

**References**

1. Cubillas R, Rockey DC. Portal hypertensive gastropathy: a review. Liver Int 30: 1094-1102, 2010.
2. Patwardhan VR, Cardenas A. Review article: the management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis. Aliment Pharmacol Ther 40: 354-362, 2014.
3. Gjorgjievska M, Cappell S. Portal hypertensive gastropathy: a systematic review of the pathophysiology, clinical presentation, natural history and therapy. World J Hepatol 8: 231-262, 2016.
4. D’Amico G, Montalbano L, Traina M, et al; The Liver Study Group of V. Cervello Hospital. Natural history of congestive gastropathy in cirrhosis. Gastroenterology 99: 1558-1564, 1990.
5. Primignani M, Carpinelli L, Pretoni P, et al; The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC). Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. Gastroenterology 119: 181-187, 2000.
6. Merli M, Nicolini G, Angeloni S, Gentili F, Attili AF, Riggio O. The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol 99: 1959-1965, 2004.
7. McCormack TT, Sims J, Eyer-Brook I, et al. Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? Gut 26: 1226-1232, 1985.
8. Stewart CA, Sanyal AJ. Grading portal gastropathy: validation of a gastropathy scoring system. Am J Gastroenterol 98: 1758-1765, 2003.
9. Sarin SK, Shahi HM, Jain M, Jain AK, Issar SK, Murthy NS. The natural history of portal hypertensive gastropathy: influence of variceal eradication. Am J Gastroenterol 95: 2888-2893, 2000.
10. Mihara M, Haruna K, Kamada T, et al. The role of endoscopic findings for the diagnosis of Helicobacter pylori infection: evaluation in a country with high prevalence of atrophic gastritis. Helicobacter 4: 40-48, 1999.
11. Takahari K, Haruna K, Ohtani H, et al. Proton pump inhibitor induction of gastric cobblestone-like lesions in the stomach. Intern Med 56: 2699-2703, 2017.
12. Hatanou Y, Haruna K, Kamada T, et al. Factors associated with gastric black spot, white flat elevated mucosa, and cobblestone-like mucosa: a cross-sectional study. Digestion 98: 185-193, 2018.
13. Simbrunner B, Beer A, Wöran K, et al. Portal hypertensive gastropathy is associated with iron deficiency anemia. Wien Klin Wochenschr 132: 1-11, 2020.
14. Tiwari PS, Ke S, Sharma D, Paudel MS, Mandal A. Prevalence of portal hypertensive gastropathy in chronic liver disease and correlation with the severity of liver disease. Cureus 11: e5454, 2019.
15. Rockey DC. An update: portal hypertensive gastropathy and colopathy. Clin Liver Dis 23: 643-658, 2019.
16. Angewa G, Kawanaka H, Uehara H, et al. Effect of laparoscopic splenectomy on portal hypertensive gastropathy in cirrhotic patients with portal hypertension. J Gastroenterol Hepatol 24: 1554-1558, 2009.
17. Kudo M, Zheng RQ, Kim SR, et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology 51 (Suppl 1): 17-26, 2008.
18. Nishizaki Y, Shiozawa H, Motogi S, Mine T, Watanabe N. [Portal hypertensive gastropathy: from clinical and pathophysiological points of view]. Jpn J Portal Hypertens 16: 58-68, 2010 (in Japa-
PH. Gastric mucosal blood flow and acid secretion in portal hypertensive rats. Gastroenterology 95: 727-733, 1988.
34. Takaya Y, Tsunoda S, Itoh M, Oshima H. [Studies on analysis of gastric mucosal blood flow by electronic endoscopic image. Especially on atrophic gastritis]. Nihon Ika Daigaku Zasshi (J Nippon Med Sch) 61: 295-305, 1994 (in Japanese, Abstract in English).
35. Calès P, Zabotto B, Meskens C, et al. Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. Gastroenterology 98: 156-162, 1990.
36. Iwao T, Toyonaga A, Sumino M, et al. Portal hypertensive gastropathy in patients with cirrhosis. Gastroenterology 102: 2060-2065, 1992.
37. Fontana RJ, Sanjay AJ, Mehta S, et al.; HALT-C Trial Group. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol 101: 983-992, 2006.
38. Kim MY, Choi H, Baik SK, et al. Portal hypertensive gastropathy: correlation with portal hypertension and prognosis in cirrhosis. Dig Dis Sci 55: 3561-3567, 2010.
39. Sarin SK, Sreenivas DV, Laboti D, Saraya A. Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension. Gastroenterology 102: 994-999, 1992.
40. Iwao T, Toyonaga A, Oho K, et al. Portal-hypertensive gastropathy develops less in patients with cirrhosis and fundal varices. J Hepatol 26: 1235-1241, 1997.
41. Merkel C, Schipilliti M, Bighin R, et al. Portal hypertension and portal hypertensive gastropathy in patients with liver cirrhosis: a haemodynamic study. Dig Liver Dis 35: 269-274, 2003.
42. De Lisi S, Peralta S, Arini A, Simone F, Craxi A. Oesophagogastroduodenoscopy in patients with cirrhosis: extending the range of detection beyond portal hypertension. Dig Liver Dis 43: 48-53, 2011.
43. Roberts DM. Chronic gastritis, alcohol, and non-ulcer dyspepsia. Gut 13: 768-774, 1972.
44. Agrawal NM, Godiwala T, Arimura A, Dajani EZ. Cytoprotection by a synthetic prostaglandin against ethanol-induced gastric mucosal damage. A double-blind endoscopic study in human subjects. Gastrointest Endosc 32: 67-70, 1986.
45. de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis 5: 645-663, 2001.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).